Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2016-03-31 AGM Information
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Other Report or Announcement
AGM Information Classification · 98% confidence The document is explicitly titled "Form 6-K, Report of Foreign Private Issuer" filed with the SEC. Form 6-K is used to report material information that a foreign private issuer is required to disclose to its home country's securities regulator or stock exchange, or that it makes public in its home country. The content announces the results of the Annual General Meeting (AGM) held on March 31, 2016, detailing resolutions passed regarding auditor appointment, director elections, and executive remuneration (stock options). While it contains AGM results, the primary regulatory filing structure is Form 6-K, which is a general reporting mechanism for foreign issuers. Since the document reports on the results of the AGM, it strongly relates to AGM Information (AGM-R). However, Form 6-K itself is a general regulatory filing. Given the specific content (AGM results) and the fact that Form 6-K is often used to disseminate material information that might otherwise be an AGM-R or DVA, we must choose the best fit. The document explicitly announces the *results* of the AGM, which aligns closely with Declaration of Voting Results & Voting Rights Announcements (DVA). However, Form 6-K is a broad SEC filing category. Since the document is a formal SEC filing (Form 6-K) reporting material information, and the content is the outcome of a shareholder meeting, DVA is a strong candidate. If DVA is not the primary focus, RNS (Regulatory Filings) is the fallback for non-standard SEC forms like 6-K that don't map perfectly to 10-K, ER, or IR. Since the core event reported is the outcome of the AGM, DVA is more specific than RNS. Let's re-evaluate the definitions: AGM-R is for presentations/materials *shared during* the AGM. DVA is for *official results* from shareholder votes. This document provides the official results. Therefore, DVA is the most accurate classification based on the content, even though the wrapper is a 6-K.
2016-03-31 English
Other Report or Announcement
AGM Information Classification · 99% confidence The document explicitly states in the table: "Attached hereto is a report on *Annual General Meeting Results.*". This directly corresponds to the definition of AGM Information (Code: AGM-R). Although it is a short announcement, the content is the result of the AGM, not just an announcement that a report is forthcoming, making AGM-R more specific than RPA or RNS. The reference to 'Annual General Meeting Results' is the key identifier.
2016-03-31 English
20-F
Annual Report FY 2015
2016-03-31 English
FORM 6-K
AGM Information Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It announces the results of the Annual General Meeting (AGM) held on March 31, 2016, including approval of auditor appointment, election of directors, and stock option grants. The content focuses on the AGM resolutions and shareholder approvals, which aligns with announcements and materials shared during the AGM. The document is not a full annual report, audit report, or financial statement, but rather an announcement of AGM outcomes. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (6938 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2016-03-31 English
Immediate Report of Meeting
Board/Management Information Classification · 98% confidence The document text consists of multiple formal declarations titled "Declaration of Director's Qualification" under Section 224(b) of the Israeli Companies' Law - 1999. These declarations detail the education, professional experience, and legal compliance status of individuals serving as directors for the company (XTL BIOPHARMACEUTICALS Ltd.). This type of filing relates directly to the composition and qualifications of the company's governing body (Board of Directors). Among the provided categories, 'Board/Management Information' (MANG) is the most appropriate fit, as it covers announcements of changes in the board of directors or senior management, which includes confirming the qualifications of directors.
2016-03-24 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement Classification · 99% confidence The document is explicitly titled "Proxy Card – Part One" and details the agenda for an "Annual General Meeting of Company Shareholders ("Meeting")". The agenda items include approving auditors, re-electing directors, and approving compensation/options for directors and the CEO. This content is directly related to soliciting shareholder votes and providing necessary information for that purpose. This aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). Although it relates to an AGM, the primary function here is the proxy solicitation material, not the AGM presentation (AGM-R) or the final voting results (DVA).
2016-03-24 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.